Shield Therapeutics plc announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was GBP 10.387 million compared to GBP 719,000 a year ago. Operating loss was GBP 2.154 million compared to GBP 9.035 million a year ago. Net loss was GBP 2.630 million compared to GBP 8.800 million a year ago. Basic loss per share from continuing operations was GBP 0.02 compared to GBP 0.08 a year ago.